NL-OMON50730已完成不适用
Effects of ciprofibrate on myocardial insulin sensitivity in pre-diabetes - Ciprofibrate and pre-diabetes
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Sex: male
- •* Age: 40-70 years
- •* BMI: 27-35 kg/m2
- •* Stable dietary habits: no weight gain or loss > 5kg in the last three months
- •* Insulin resistant: glucose clearance rate below < 360 ml/kg/min, as
- •determined using OGIS120
排除标准
- •* Patients with a cardiac disease or with instable angina
- •* Patients with hepatic or renal failure
- •* Haemoglobin <7.8 mmol/l
- •* In case of an abnormal ECG in rest: this will be discussed with the
- •responsible medical doctor
- •* HbA1c > 6.5%
- •* Diagnosed with type 1 or type 2 diabetes mellitus
- •* Patients with alcohol abuse
- •* Use of a fibrate
- •* Medication use known to interfere with glucose homeostasis/metabolism
- •* Use of anti-coagulants, excluding platelet aggregation inhibitors
- •* Subjects who do not want to be informed about unexpected medical findings
- •during the screening /study, or do not wish that their physician is informed,
- •cannot participate in the study.
- •* Subjects who intend to donate blood during the intervention or subjects who
- •have donated blood less than three months before the start of the intervention.
- •* Participation in another biomedical study within 1 month before the first
- •screening visit
- •* Any condition, disease or abnormal laboratory test result that, in the
- •opinion of the Investigator, would interfere with the study outcome, affect
- •trial participation or put the subject at undue risk
- •* Any contra-indication to MRI scanning.
- •* Participation in earlier research or medical examinations in the past 3
- •months that included PET/MRI scanning
研究者
相似试验
进行中（未招募）
1 期
Ciprofibrate and pre-diabetesInsulin resistance, diastolic cardiac failure, mitochondrial functionEUCTR2018-001663-22-NLMaastricht University12
已完成
3 期
Ciprofibrate and Pre-diabetesMyocardial Insulin SensitivityImpaired Glucose MetabolismDiastolic DysfunctionNCT03662984Maastricht University Medical Center11
招募中
不适用
Effects of bezafibrate and fenofibrate on insulin sensitivity in patients with type 2 diabetes mellitus by the glucose clamp technique and the meal tolerance test.Type 2 diabetes mellitusJPRN-UMIN000012462Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine20
已完成
4 期
Effects of Fenofibrate on Intramyocardial Triglyceride Content and Left Ventricular Myocardial Function in patients with Type 2 Diabetes and HypertriglyceridemiaHypertriglyceridemiaACTRN12614001086651Dr Arnold Ng60
进行中（未招募）
不适用
Efficacy of fenofibrate treatment on the insulin sensitivity and pancreas ß-cell function in obese patients with hypertriglyceridemia.Patients non-diabetic, obese with hypertriglyceridemia (previously untreated with fibrate).EUCTR2005-005698-31-HUational Medical Center (Országos Gyógyintézeti Központ)40